Thom Frielink MSc, MBA


Thom has 7 years of consultancy experience in raising funding for biopharmaceutical and medtech companies as advisor for Catalyze, Health-Holland and FFUND. In these functions Thom was involved in raising over €85 million non-dilutive capital and has developed in-depth knowledge on a wide range of topics in Life Sciences (including ATMPs, small molecules, Medical Devices (class I, II and III) and IVDs). In addition, he was the CEO of 2ndB, an Organ-on-Chip start-up focused on creating neuron-based-networks using microfluidics for the pre-clinical prediction of efficacy for Parkinsons Disease therapeutics. Thom has a BSc and MSc in Science and Innovation Management at Utrecht University. In 2023, Thom has completed his MBA with great distinction (magna cum laude) at the Vlerick Business School in Belgium.

Our other team members

We are a venture capital firm specializing in seed investments for innovative early-stage companies. Curie Capital typically takes on the role of lead investor. Our team comprises life science experts and business analysts who offer guidance to life science companies throughout the entire research and development process.

Han de Groot, MSc


Mariette van der Velden, MSc


Olivier Tak

Junior partner